Please login to the form below

Not currently logged in
Email:
Password:

Lilly/Boehringer diabetes drug approved

The US Food and Drug Administration has granted marketing approval to a type 2 diabetes drug developed through a partnership between Lilly and Boehringer Ingelheim

The US Food and Drug Administration (FDA) has granted marketing approval to a type 2 diabetes drug developed through a partnership between Lilly and Boehringer Ingelheim.

Approval of the drug, Tradjenta (linagliptin), is the first regulatory milestone in the companies' worldwide diabetes alliance since the partnership was formed in January of this year. 

Tradjenta is indicated to lower blood sugar in adults when used in conjunction with a diet and exercise programme. The drug can be used as monotherapy or in combination with other commonly prescribed diabetes medications. 

The therapy increases the level of hormones that stimulate the release of insulin after a meal by blocking the enzyme dipeptidyl peptidase-4 (DPP-4). It is the first of the DPP-4 inhibitors to be approved at one dosage strength (5 mg, once daily), with no dose adjustment necessary in patients with kidney or liver impairment.

The approval was based on a New Drug Application (NDA) that contained data from eight double-blind, placebo-controlled clinical studies involving about 3,800 patients with type 2 diabetes.

Tradjenta is currently under regulatory review in the EU and Japan. The product will be available as a tablet that can be taken with or without food.

"This approval provides another treatment option for the millions of Americans with Type 2 diabetes," said Mary Parks, director of the Division of Metabolism and Endocrinology Products in the FDA's Center for Drug Evaluation and Research. "It is effective when used alone or when added to existing treatment regimens."

4th May 2011

Share

Related Hub content

    Your search did not contain any words. Please try again.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
MJL

Clients who’ve found out how hard we work at keeping their brands performing tend to stay with us. That’s why...

Latest intelligence

Online Physician Communities
M3 improves personalisation of pharma engagement with doctors
Launches new messaging service on Doctors.net.uk...
Digital Futures 2014 slide deck
Full slides, including survey data, from PMLiVE's digital pharma marketing online event...
The Chinese diabetes challenge
Marketing, communications and commercial relationships in China are full of pitfalls for the unwary, but not without great potential ...